Antiangiogenic therapy in breast cancer
نویسندگان
چکیده
Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth factor receptor 2(HER2)-negative breast cancer, the addition of bevacizumab to standard chemotherapy improved consistently progression-free survival (PFS), however, without effect on overall survival (OS). In early breast cancer bevacizumab increased the pathologic complete response rate (pCR) after neoadjuvant therapy, but adjuvant trials did not demonstrate an effect on long-term survival. Unfortunately, despite extensive research, there is still no biomarker for bevacizumab efficacy available, making patient selection difficult. This review summarizes all phase III trials investigating efficacy and toxicity of bevacizumab in early, locally advanced and metastatic breast cancer. It recapitulates the main toxicities, gives an overview on biomarker studies and discusses the role and future aspects of antiangiogenic therapy in breast cancer.
منابع مشابه
Evaluation of the cytotoxic effect of green-synthesized Zinc Oxide nanoparticles with Ceratonia siliqua extract on the breast cancer cell line (MDA-MB231) and its antiangiogenic effects
Introduction Green biosynthesis of the metallic nanoparticles is considered as one of the effective method for cancer treatment with minimum side effects. The objective of this study was the evaluation of cytotoxicity of zinc oxide (ZnO) nanoparticles synthesized with Ceratonia siliqua extract on the breast cancer cells and assessment of anti-angiogenesis properties of these nanoparticles in t...
متن کاملNear-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
BACKGROUND Near-infrared diffuse optical imaging (DOSI) has been recently accepted as a method to assess tumor vascularity and oxygenation by measuring tissue hemoglobin (Hb) concentration. It is expected that DOSI could be used to monitor changes in vascularity after antiangiogenic therapy. METHODS A patient with advanced breast cancer was treated with single-agent bevacizumab followed by ad...
متن کاملInitiation of Aspirin Therapy Modulates Angiogenic Protein Levels in Women with Breast Cancer Receiving Tamoxifen Therapy
Aspirin has a range of antineoplastic properties linked to inhibition of cyclooxygenase enzymes in tumor cells, platelet inhibition and to inhibition of angiogenesis. We undertook a prospective study to determine the influence of a 45-day course of aspirin therapy on circulating and intraplatelet levels of selected proangiogenic (vascular endothelial growth factor [VEGF]) and antiangiogenic (th...
متن کاملImproving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include bevacizumab (Avastin), the anti-VEGF monoclonal antibody. Thus far, bevacizumab appears to induce clinical benefit in patients who have advanced metastatic disease only or primarily when it is com...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2017